The U.S. Food and Drug Administration (FDA) announced on November 9 the issuance of its final guidance for the development of artificial pancreas systems. The guidance incorporates nearly all of JDRF’s recommendations. This news represents a milestone victory for JDRF and the type 1 diabetes (T1D) community, as the technology is viewed by medical experts […]
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
JDRF-funded researchers have developed a formulation of liquid glucagon that remains stable and viable for long periods of time and thus may be usable in standard diabetes pumps. The research represents advancement toward the routine delivery of glucagon for people with T1D and may also facilitate the development of bihormonal closed-loop artificial pancreas systems.
JDRF has partnered with San Diego–based medical company Dexcom, Inc. to support the manufacture of a so-called smart transmitter prototype, which will be available for research purposes before it will be commercially available. The technological advance not only would reduce the number of devices a person would have to wear with an artificial pancreas system, but would also enable wireless connectivity among these devices—an important feature that would give people with T1D the freedom of movement while participating in real-life outpatient studies.
The JDRF Artificial Pancreas Project has significantly accelerated progress toward the delivery of the first artificial pancreas (AP) systems to people with diabetes. Research progress has been exceptional with multiple studies in controlled settings demonstrating that AP systems can significantly reduce high and low blood sugar levels automatically. For people with diabetes to realize the […]
A simple insulin-infusion warming device, called the InsuPatch, accelerates insulin delivery into the bloodstream by as much as 35 minutes. Speeding up the delivery and action of insulin and reducing the amount of time patients spend in a hyperglycemic state potentially reduces the risk of complications that result from the disease.
The closed-loop artificial pancreas, which combines an insulin pump with a glucose monitor, has been successfully tested on people in controlled hospital settings. Now, researchers believe that it is time to try this innovation in real-life environments. Last summer, JDRF formed a panel of experts to provide advice about how to bring this technology out […]
In another key step forward on the road to an artificial pancreas, JDRF has launched a research program to speed the development of faster-acting insulin. Through the initiative, JDRF is funding investigators at leading academic institutions to test novel insulin formulations and delivery systems. The goal is to develop faster-acting insulin for use in an […]
These developments represent a giant step forward on the path to achieving an artificial pancreas, a fully automated system that can dispense insulin to patients based on real-time changes in blood sugar levels. Even the earliest systems could bring dramatic changes in the quality of life for people with type 1 diabetes.
Continuous glucose monitors are more than simply devices of convenience for people with diabetes—they are tools that can substantially improve blood sugar control in people of all ages when used regularly, without increasing the risk of dangerous low blood sugar. The growing evidence of the benefits of CGM underscores the importance of continued research into a closed-loop artificial pancreas, a system that uses CGM data to automatically deliver the right amount of insulin through a pump.